A hybrid treatment modality of a subtrochanteric femoral fracture in a patient with osteoporosis due to a renal Fanconi syndrome: a case report

Abstract

A 24-year-old male with an idiopathic renal Fanconi syndrome presented to our ER after a low-energetic fall. Conventional imaging revealed a right subtrochanteric femoral fracture, severely decreased bone quality and cannulated collum femoris screws on the contralateral side. Regular plate-screw osteosynthesis or cephalomedullary implantation was deemed insufficient, due to a high iatrogenic and periprosthetic fracture probability. The decision was made to perform a plate-screw osteosynthesis combined with an intramedullary polymer bone enhancement (IlluminOss), to minimize this risk. No complications occurred perioperatively. The patient was able to walk independently two months postoperatively. This case shows that use of polymer implant as an enhancement of osteosynthesis in repair of fractures in the Fanconi syndrome is a safe and possible useful treatment method.

How I do it: Percutaneous stabilization of symptomatic sacral and periacetabular metastatic lesions with photodynamic nails

“…The authors report cortical bridging and elimination of the fracture line on X-ray in all cases, with maintenance of reduction in 84% of cases. While a particular advantage of PDN is that can serve as an augmentation medium for metal implant fixation through pathologic bone,21 either as a part of initial treatment or as a result of a complication thereof, the efficacy of PDN as a standalone implant in the stabilization of bilateral femoral nonunions in a young, active patient with osteogenesis imperfecta has been shown by members of our group 11.…”

Operative Fixation of a Humeral Shaft Periprosthetic Fracture After IlluminOss

“…The clinical utility of PBSS is vast because authors have reported outcomes in both patients who required prophylactic fixation for impending fractures, as well as operative fixation of acute, traumatic, and/or pathologic extra-articular fractures 7,[11][12][13][14] . Despite early clinical success in Europe, the Illumi-nOss PBSS did not become approved by the US Food and Drug Administration until 2020 4,11 .…”